Jacalyn M. Rosenblatt
Expertise in
18
conditions

Dr. Jacalyn M. Rosenblatt

Internal Medicine
330 Brookline Avenue, Shapiro 7, 
Boston, MA 
On Staff At
Expertise in
18
conditions
330 Brookline Avenue, Shapiro 7, 
Boston, MA 

Overview

Jacalyn Rosenblatt is an Internal Medicine provider practicing medicine in Boston, Massachusetts.

Dr. Rosenblatt is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Rosenblatt is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 80 peer reviewed articles and participating in 11 clinical trials.

Graduate Institution

McGill University Faculty Of Medicine

Residency

McGill University Faculty of Medicine

Specialties

Internal Medicine

Licenses

Internal Medicine in MA

Board Certifications

American Board Of Internal Medicine

Fellowships

Beth Israel Deaconess Medical Center
McGill University Faculty of Medicine

Hospital Affiliations

Beth Israel Deaconess Medical Center

Languages Spoken

English
French

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 7, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: Daratumumab
Study Phase: Phase 2
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: CART-ddBCMA
Study Phase: Phase 1
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Other, Biological
Study Drug: Dendritic Cell Fusion Vaccine
Study Phase: Phase 2
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients
A Phase I Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Alone and in Conjunction With Decitabine Following Allogeneic Transplantation in AML Patients
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Biological
Study Drugs: Decitabine, DC/AML fusion cells
Study Phase: Phase 1
A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 1
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Enrollment Status: Terminated
Publish Date: June 22, 2023
Intervention Type: Biological, Drug
Study Drugs: Nivolumab, DC/Myeloma Fusions/GM-CSF
Study Phase: Phase 2
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 18, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: Busulfan, Fludarabine, Tacrolimus, Methotrexate, GM-CSF-Positive GVAX Vaccine
Study Phase: Phase 2
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: August 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

80 Total Publications

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.
Journal: Nature communications
Published: August 01, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Adnan Majid
Internal Medicine
Expertise in
22
conditions
Dr. Adnan Majid
Internal Medicine

Beth Israel Deaconess Medical Center

185 Pilgrim Road, Farr Building, 1st Floor, 
Boston, MA 
 (0.3 miles away)
617-632-8252
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Adnan Majid is an Internal Medicine provider practicing medicine in Boston, Massachusetts. Dr. Majid is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Tracheobronchomalacia, Pleural Effusion, Acquired Tracheomalacia, Advanced Bronchoscopy, and Endoscopy. Dr. Majid is board certified in American Board Of Internal Medicine.

Expertise in
20
conditions
Dr. Nezam H. Afdhal
Internal Medicine
Expertise in
20
conditions
Dr. Nezam H. Afdhal
Internal Medicine

BIDMC - Division Of Gastroenterology/Liver Center

110 Francis Street, Suite 8E, 
Boston, MA 
 (0.3 miles away)
617-632-1070
Languages Spoken:
English, Farsi
See accepted insurances

Nezam Afdhal is an Internal Medicine provider practicing medicine in Boston, Massachusetts. Dr. Afdhal is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy.

Expertise in
23
conditions
Dr. Robert W. Yeh
Internal Medicine | Cardiology
Expertise in
23
conditions
Dr. Robert W. Yeh
Internal Medicine | Cardiology

BIDMC - Division Of Cardiology

185 Pilgrim Road, Baker 4, 
Boston, MA 
 (0.3 miles away)
617-667-8800
Languages Spoken:
English
See accepted insurances

Robert Yeh is a Cardiologist and an Internal Medicine provider practicing medicine in Boston, Massachusetts. Dr. Yeh is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Heart Attack, Coronary Heart Disease, Angina, Percutaneous Coronary Intervention (PCI), and Stent Placement. Dr. Yeh is board certified in American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Jacalyn M. Rosenblatt

How do I make an appointment with Dr. Jacalyn M. Rosenblatt?

You can book an appointment with Dr. Jacalyn M. Rosenblatt by calling their office at 617-667-9920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jacalyn M. Rosenblatt a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jacalyn M. Rosenblatt is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jacalyn M. Rosenblatt specialize in?

While Dr. Jacalyn M. Rosenblatt is a Internal Medicine, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Jacalyn M. Rosenblatt participate in research or clinical trials?

Yes. Dr. Jacalyn M. Rosenblatt has published 80 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Jacalyn M. Rosenblatt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jacalyn M. Rosenblatt accept my insurance?

Dr. Jacalyn M. Rosenblatt accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-667-9920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenblatt's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile